Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AZD4547 in advanced solid tumors and FGFR2/3-altered urothelial carcinoma
CTR20210782Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib in Nonhematologic neoplasms, transitional cell carcinoma (TCC), sponsored by Abbisko Therapeutics. Started Jun 2021; status: active.
02
Drugs
fexagratinib
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20210782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210782.